Cigna's Evernorth to Offer Humira Biosimilar Without Out-of-Pocket Fee
By Ben Glickman
Cigna Group-owned Evernorth Health Services said Thursday it would provide a Humira biosimilar with no out-of-pocket fees starting in June.
The pharmacy and benefits provider said the biosimilar for Humira, used as a treatment for rheumatoid arthritis, Crohn's disease and other inflammatory conditions, would be available to eligible patients at its specialty pharmacy Accredo.
The company said the biosimilar price would be about 85% lower than the Humira list price. Evernorth said more than 100,000 Accredo patients currently use Humira or a biosimilar.
Plans for a $0 out-of-pocket Humira biosimilar offering was initially announced by Evernorth in March.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 25, 2024 17:25 ET (21:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom